Skip to content

Ayahuasca: all studies

Page 129 of 167: studies 1,281 to 1,290 of 1,662, newest first. Back to the ayahuasca overview

Research

Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens

Dermatitis April 18, 2024 Syed Minhaj Rahman, Yousef Salem, Aamir Hussain 4 citations

Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and...

DOI: 10.1089/derm.2023.0292 (opens in new tab) Psilocybin Hallucinogen Trips architecture Dermatology

Für ein besseres Verständnis anhaltender Wahrnehmungsstörungen nach der Einnahme klassischer Psychedelika

Fortschritte der Neurologie · Psychiatrie April 1, 2024 Stefan Borgwardt, Tomislav Majić, Mihai Avram et al.

Klassische Psychedelika wie Psilocybin, Lysergsäurediethylamid (LSD), Ayahuasca oder 5-Methoxy-Dimethyltryptamin (5-MeO-DMT) stehen wieder vermehrt im Fokus des psychiatrisch-psychotherapeutischen und neurowissenschaftlichen Interesses. Dies ist vor allem auf aktuelle klinische Studien zurückzuführen, die einen möglichen therapeutischen Nutzen von Psychedelika in der Behandlung verschiedener...

Toward a More Sustainable Sample Preparation in Phytochemistry: Case Studies in Four Subclasses of Alkaloids.

Journal of Natural Products March 22, 2024 Lucas Apolinário Chibli, Bruna Ribeiro de Lima, Ariadne Magalhães Carneiro et al. 4 citations

The fact that alkaloids are bases has been the most explored chemical feature of their extraction and purification procedures. The main drawback of these procedures is that they employ undesirable chemicals, with HCl and CH2Cl2 probably being the most commonly employed chemicals in their subsequent steps. This work tested the hypothesis that advantages in recovery efficiency support this common...

DOI: 10.1021/acs.jnatprod.3c01048 (opens in new tab) Full text (opens in new tab) Sustainable chemistry Natural compounds Plant extracts Green extraction +1

Psychedelic Therapy as Form of Life

Neuroethics March 16, 2024 Nicolas Langlitz, Alex K. Gearin 26 citations

Abstract In the historical context of a crisis in biological psychiatry, psychedelic drugs paired with psychotherapy are globally re-emerging in research clinics as a potential transdiagnostic therapy for treating mood disorders, addictions, and other forms of psychological distress. The treatments are poised to soon shift from clinical trials to widespread service delivery in places like...

Altered states of consciousness

March 13, 2024 Susan Blackmore, Emily T. Troscianko 46 citations

Altered states of consciousness (ASCs) are surprisingly hard to define and to measure. Neither ‘subjective’ methods (like verbal reports) nor ‘objective’ measures (such as how the state is induced, or physiological and behavioural criteria) are entirely satisfactory. Attempts to map ASCs are reviewed, including two- or three-dimensional maps such as Tart&s;s and Laureys’, and Hobson&s;s AIM...

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

European Neuropsychopharmacology March 1, 2024 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B Silva et al. 25 citations

Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at...

DOI: 10.1016/j.euroneuro.2023.12.006 (opens in new tab) Full text (opens in new tab) Entheogens Clinical trial Dose-response study Mood disorders +6

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

Current Psychiatry Research and Reviews January 21, 2024 Payal Ghosh, Debjeet Sur 1 citation

: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic...

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Current Neuropharmacology January 5, 2024 Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al. 73 citations

Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

medRxiv January 4, 2024 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 5 citations preprint

Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...

Étendre la noosphère et ré-élever l’anthropos

Le Portique 2024 Pieter Lemmens

Cet article considère les potentiels noétiques des psychédéliques en tant que pharmaka dans le cadre stieglerien de l’organologie et de la pharmacologie de la noèse. Il vise à soutenir, brièvement et provisoirement, que les expériences médiées par les pharmaka psychédéliques peuvent, d’une part, être mieux comprises à partir de ce cadre « spirituo-matérialiste » mais, d’autre part, peuvent...